{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:29:54Z","timestamp":1793204994949,"version":"4.5.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"Importance<\/jats:title>Alzheimer disease (AD), a neurodegenerative disease characterized by \u03b2-amyloid plaques and \u03c4 tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the safety and efficacy of crenezumab, a humanized monoclonal immunoglobulin G4 antibody targeting \u03b2-amyloid oligomers, in participants with prodromal to mild (early) AD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Two phase 3 multicenter randomized double-blind placebo-controlled parallel-group efficacy and safety studies of crenezumab in participants with early AD, CREAD and CREAD2, were initiated in 2016 and 2017, respectively, and were designed to evaluate the efficacy and safety of crenezumab in participants with early AD. CREAD (194 sites in 30 countries) and CREAD2 (209 sites in 27 countries) were global multicenter studies. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. A total of 3736 and 3664 participants were screened in CREAD and CREAD2, respectively. Both trials enrolled individuals aged 50 to 85 years with early AD. Participants with some comorbidities and evidence of cerebral infarction or more than 4 microbleeds or areas of leptomeningeal hemosiderosis on magnetic resonance imaging were excluded. After 2923 and 2858 were excluded, respectively, 813 participants in CREAD and 806 in CREAD2 were randomly assigned in a 1:1 ratio to either placebo or crenezumab. In the final analysis, there were 409 participants in the placebo group and 404 in the crenezumab group in CREAD and 399 in the placebo group and 407 in the crenezumab group in CREAD2. Data were analyzed up until January 2019 and August 2019, respectively.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants received placebo or 60 mg\/kg crenezumab intravenously every 4 weeks for up to 100 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was change from baseline to week 105 in Clinical Dementia Rating\u2013Sum of Boxes (CDR-SB) score.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 813 participants in CREAD (mean [SD] age, 70.7 [8.2] years; 483 female and 330 male) and 806 in CREAD2 (mean [SD] age, 70.9 [7.7] years; 456 female and 350 male). Baseline characteristics were balanced between both groups. The between-group difference in mean change from baseline in CDR-SB score (placebo minus crenezumab) was \u22120.17 (95% CI, \u22120.86 to 0.53; P<\/jats:italic>\u2009=\u2009.63) at week 105 in the CREAD study (88 placebo; 86 crenezumab). Compared with previous trials, no new safety signals were identified, and amyloid-related imaging abnormalities with edema were rare, mild, and transient. No meaningful changes in AD biomarkers were observed. Both studies were discontinued following a preplanned interim analysis indicating that CREAD was unlikely to meet the primary end point.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Crenezumab was well tolerated but did not reduce clinical decline in participants with early AD.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifiers: CREAD, NCT02670083<\/jats:ext-link>; CREAD2, NCT03114657<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2022.2909","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:31:54Z","timestamp":1663601514000},"page":"1113","source":"Crossref","is-referenced-by-count":223,"title":["Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease"],"prefix":"10.1001","volume":"79","author":[{"given":"Susanne","family":"Ostrowitzki","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bittner","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaycee M.","family":"Sink","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Mackey","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rabe","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[{"name":"Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cassetta","sequence":"additional","affiliation":[{"name":"Fatebenefratelli Foundation, Associazione Fatebenefratelli Per la Ricerca Division, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Woodward","sequence":"additional","affiliation":[{"name":"Austin Health Continuing Care Clinical Service Unit, Heidelberg, Germany"},{"name":"University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[{"name":"Research Center and Memory Clinic, Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"van Dyck","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Research Unit, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Selkoe","sequence":"additional","affiliation":[{"name":"Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Schneider","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Blondeau","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Quartino","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"},{"name":"Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clayton","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dolton","sequence":"additional","affiliation":[{"name":"Roche Products Australia Pty Ltd, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Dang","sequence":"additional","affiliation":[{"name":"Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Sanofi Genzyme, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Ostaszewski","sequence":"additional","affiliation":[{"name":"Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Sanabria-Boh\u00f3rquez","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rabbia","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Toth","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Eichenlaub","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Smith","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A.","family":"Honigberg","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle S.","family":"Doody","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi220054r1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u00df-targeting therapies for Alzheimer disease.","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"noi220054r2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-019-0553-5","article-title":"Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A\u00df.","volume":"11","author":"Meilandt","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"21","key":"noi220054r3","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"noi220054r4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE).","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"noi220054r5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease treated with escalating doses for up to 133 weeks.","volume":"76","author":"Guthrie","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"noi220054r6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi220054r7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"8","key":"noi220054r8","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer\u2019s research consortium study.","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"key":"noi220054r9","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"noi220054r10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease.","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"3","key":"noi220054r11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state.\u201d A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"noi220054r12","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"noi220054r13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia.","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"issue":"2","key":"noi220054r14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.","volume":"12","author":"Kaufer","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"noi220054r15","first-page":"21","article-title":"Quality of life in Alzheimer\u2019s disease: patient and caregiver reports.","volume":"5","author":"Logsdon","year":"1999","journal-title":"J Ment Health Aging"},{"issue":"7","key":"noi220054r16","doi-asserted-by":"publisher","first-page":"PA389","DOI":"10.1016\/j.jval.2016.09.244","article-title":"Cross-cultural adaptation of the Zarit Caregiver Interview for Alzheimer\u2019s Disease (ZCI-AD) and the Caregiver Global Impression scales in 13 languages.","volume":"19","author":"Le Scouiller","year":"2016","journal-title":"Value Health"},{"issue":"10","key":"noi220054r18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"75","key":"noi220054r19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jalz.2019.06.2638","article-title":"Exploring the need for robust biomarker assays in Alzheimer\u2019s disease and other neurodegenerative diseases.","volume":"15","author":"Blennow","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"2","key":"noi220054r20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ana.v86.2","article-title":"Target engagement in an Alzheimer trial: crenezumab lowers amyloid \u00df oligomers in cerebrospinal fluid.","volume":"86","author":"Yang","year":"2019","journal-title":"Ann Neurol"},{"issue":"12","key":"noi220054r21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"1","key":"noi220054r22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","article-title":"Safety and efficacy of anti-amyloid-\u00df immunotherapy in Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J Neuroimmune Pharmacol"},{"key":"noi220054r23","doi-asserted-by":"publisher","first-page":"P1668","DOI":"10.1016\/j.jalz.2018.07.009","article-title":"DT-01-07: treatment of early AD subjects with BAN2401, an anti-A\u00df protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline.","volume":"14","author":"Swanson","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"18","key":"noi220054r24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"noi220054r25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for Alzheimer disease\u2014the FDA\u2019s perspective.","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"11","key":"noi220054r26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/alz.v16.11","article-title":"Cognitive outcomes in trials of two BACE inhibitors in Alzheimer\u2019s disease.","volume":"16","author":"Wessels","year":"2020","journal-title":"Alzheimers Dement"},{"key":"noi220054r27","doi-asserted-by":"publisher","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of crenezumab complex with A\u00df shows loss of \u00df-hairpin.","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"noi220054r28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer\u2019s disease.","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi220054r29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2174\/1567205017666200302122307","article-title":"Mechanistic modeling of soluble A\u00df dynamics and target engagement in the brain by anti-A\u00df mAbs in Alzheimer\u2019s disease.","volume":"17","author":"Ferl","year":"2020","journal-title":"Curr Alzheimer Res"},{"key":"noi220054r17","volume-title":"The Hidden Victims of Alzheimer\u2019s Disease: Families Under Stress","author":"Zarit","year":"1985"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2796551\/jamaneurology_ostrowitzki_2022_oi_220054_1667929377.75124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:09:46Z","timestamp":1668442186000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2796551"}},"subtitle":["Two Phase 3 Randomized Placebo-Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}